Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 101 articles: HTML format

Single Articles

April 2024
1. HU H, Zhang J, Li Y, Wang X, et al
   Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
   J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889.
   PubMed     Abstract available
   
   
   
2. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
   Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
   J Clin Oncol. 2024;42:1098-1101.
   PubMed    
   
   
   March 2024
3. GALLOIS C, Shi Q, Pederson LD, Andre T, et al
   Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
   J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326.
   PubMed     Abstract available
   
   
   
4. GAO Z, Zhu Z, Li K
   Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
   J Clin Oncol. 2024;42:1088.
   PubMed    
   
   
   
5. MEHTSUN WT, Gupta S
   Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer-We Must Do Better.
   J Clin Oncol. 2024 Mar 15:JCO2302186. doi: 10.1200/JCO.23.02186.
   PubMed    
   
   
   
6. DOMINGO E, Kelly C, Hay J, Sansom O, et al
   Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
   J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648.
   PubMed     Abstract available
   
   
   
7. LORIA A, Ramsdale EE, Aquina CT, Cupertino P, et al
   From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer.
   J Clin Oncol. 2024;42:876-880.
   PubMed    
   
   
   
8. FOKAS E, Smith JJ, Garcia-Aguilar J, Glynne-Jones R, et al
   Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited.
   J Clin Oncol. 2024;42:872-875.
   PubMed     Abstract available
   
   
   
9. BATTAGLIN F, Ou FS, Qu X, Hochster HS, et al
   HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
   J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507.
   PubMed     Abstract available
   
   
   
10. SHAH SC, Camargo MC, Lamm M, Bustamante R, et al
    Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
    J Clin Oncol. 2024 Mar 1:JCO2300703. doi: 10.1200/JCO.23.00703.
    PubMed     Abstract available
    
    
    February 2024
11. RAHBARI NN, Biondo S, Frago R, Feisst M, et al
    Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
    J Clin Oncol. 2024 Feb 27:JCO2301540. doi: 10.1200/JCO.23.01540.
    PubMed     Abstract available
    
    
    
12. VERHEIJ FS, Omer DM, Williams H, Lin ST, et al
    Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.
    J Clin Oncol. 2024;42:500-506.
    PubMed     Abstract available
    
    
    
13. CHEN L, Wang Y, Cai C, Ding Y, et al
    Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
    J Clin Oncol. 2024 Feb 5:JCO2301080. doi: 10.1200/JCO.23.01080.
    PubMed     Abstract available
    
    
    January 2024
14. PINTO C, Orlandi A, Normanno N, Maiello E, et al
    Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study.
    J Clin Oncol. 2024 Jan 5:JCO2301021. doi: 10.1200/JCO.23.01021.
    PubMed     Abstract available
    
    
    
15. DOSSA F, Baxter NN
    Understanding Tradeoffs in the Treatment of Rectal Cancer From the Patient Perspective.
    J Clin Oncol. 2024;42:120-121.
    PubMed    
    
    
    
16. EL SISSY C, Kirilovsky A, Lagorce Pages C, Marliot F, et al
    International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy.
    J Clin Oncol. 2024;42:70-80.
    PubMed     Abstract available
    
    
    December 2023
17. STEBBING J, Schlechter BL
    Genes and Race in Colon Cancer.
    J Clin Oncol. 2023 Dec 7:JCO2302094. doi: 10.1200/JCO.23.02094.
    PubMed    
    
    
    November 2023
18. INNOCENTI F, Mu W, Qu X, Ou FS, et al
    DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
    J Clin Oncol. 2023 Nov 22:JCO2300825. doi: 10.1200/JCO.23.00825.
    PubMed     Abstract available
    
    
    
19. DE GRAMONT A, Figer A, Seymour M, Homerin M, et al
    Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.
    J Clin Oncol. 2023;41:5080-5089.
    PubMed     Abstract available
    
    
    
20. 
    JCO Flashback: Exploring an Effective Drug Combination for Colorectal Cancer (2000).
    J Clin Oncol. 2023;41:5079.
    PubMed    
    
    
    
21. MAYER RJ
    Flashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal Cancer.
    J Clin Oncol. 2023;41:5077-5078.
    PubMed    
    
    
    
22. DUVIVIER HL, Rothe M, Mangat PK, Garrett-Mayer E, et al
    Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    J Clin Oncol. 2023;41:5140-5150.
    PubMed     Abstract available
    
    
    
23. HEYMER EJ, Jozwiak K, Kremer LC, Winter DL, et al
    Cumulative Absolute Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors: A PanCareSurFup Study.
    J Clin Oncol. 2023 Nov 16:JCO2300452. doi: 10.1200/JCO.23.00452.
    PubMed     Abstract available
    
    
    
24. NOGUEIRA LM, May FP, Yabroff KR, Siegel RL, et al
    Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States.
    J Clin Oncol. 2023 Nov 8:JCO2300539. doi: 10.1200/JCO.23.00539.
    PubMed     Abstract available
    
    
    
25. ZWANENBURG ES, El Klaver C, Wisselink DD, Punt CJA, et al
    Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
    J Clin Oncol. 2023 Nov 3:JCO2202644. doi: 10.1200/JCO.22.02644.
    PubMed     Abstract available
    
    
    October 2023
26. IOFFE D, Dotan E
    Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials.
    J Clin Oncol. 2023 Oct 19:JCO2301337. doi: 10.1200/JCO.23.01337.
    PubMed     Abstract available
    
    
    
27. HALL WA, Li J, You YN, Gollub MJ, et al
    Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
    J Clin Oncol. 2023;41:4643-4651.
    PubMed     Abstract available
    
    
    
28. WANG G, Liu Z
    Alcohol Intake Associated With Increased Risk of Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Oct 2:JCO2301548. doi: 10.1200/JCO.23.01548.
    PubMed    
    
    
    September 2023
29. 
    Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
    J Clin Oncol. 2023 Sep 12:JCO2301858. doi: 10.1200/JCO.23.01858.
    PubMed    
    
    
    August 2023
30. RUPPERT R, Junginger T, Kube R, Strassburg J, et al
    Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study.
    J Clin Oncol. 2023;41:4025-4034.
    PubMed     Abstract available
    
    
    
31. LONARDI S, Rasola C, Lobefaro R, Rossini D, et al
    Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation.
    J Clin Oncol. 2023 Aug 3:JCO2300506. doi: 10.1200/JCO.23.00506.
    PubMed     Abstract available
    
    
    July 2023
32. SALTZ LB, Clarke S, Diaz-Rubio E, Scheithauer W, et al
    Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
    J Clin Oncol. 2023;41:3663-3669.
    PubMed     Abstract available
    
    
    
33. GIANTONIO BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, et al
    Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200.
    J Clin Oncol. 2023;41:3670-3675.
    PubMed     Abstract available
    
    
    
34. O'REILLY EM
    Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3661-3662.
    PubMed    
    
    
    
35. BASCH E, Dueck AC, Mitchell SA, Mamon H, et al
    Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
    J Clin Oncol. 2023;41:3724-3734.
    PubMed     Abstract available
    
    
    
36. TOURNIGAND C, Andre T, Achille E, Lledo G, et al
    FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study.
    J Clin Oncol. 2023;41:3469-3477.
    PubMed     Abstract available
    
    
    
37. GOLDBERG RM, Sargent DJ, Morton RF, Fuchs CS, et al
    A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3461-3468.
    PubMed     Abstract available
    
    
    
38. VENOOK AP
    Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer.
    J Clin Oncol. 2023;41:3459-3460.
    PubMed    
    
    
    June 2023
39. MONTRONI I, Ugolini G, Saur NM, Rostoft S, et al
    Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study.
    J Clin Oncol. 2023 Jun 30:JCO2202195. doi: 10.1200/JCO.22.02195.
    PubMed     Abstract available
    
    
    
40. LORIA A, Fleming FJ
    Restoration of Quality of Life and Functional Recovery After Colorectal Cancer Surgery in Older Adults.
    J Clin Oncol. 2023 Jun 30:JCO2301066. doi: 10.1200/JCO.23.01066.
    PubMed    
    
    
    
41. IRAJIZAD E, Fahrmann JF, Marsh T, Vykoukal J, et al
    Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
    J Clin Oncol. 2023 Jun 28:JCO2202424. doi: 10.1200/JCO.22.02424.
    PubMed     Abstract available
    
    
    
42. STINTZING S, Heinrich K, Tougeron D, Modest DP, et al
    FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF(V600E)-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
    J Clin Oncol. 2023 Jun 23:JCO2201420. doi: 10.1200/JCO.22.01420.
    PubMed     Abstract available
    
    
    
43. AMADO RG, Wolf M, Peeters M, Van Cutsem E, et al
    Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3278-3286.
    PubMed     Abstract available
    
    
    
44. 
    JCO Flashback: Predictive Value of KRAS Mutations on the Outcomes of Panitumumab Monotherapy in Colorectal Cancer.
    J Clin Oncol. 2023;41:3277.
    PubMed    
    
    
    
45. KO AH
    Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer.
    J Clin Oncol. 2023;41:3275-3276.
    PubMed    
    
    
    
46. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    PubMed     Abstract available
    
    
    
47. SEAGLE HM, Keller SR, Tavtigian SV, Horton C, et al
    Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2202378. doi: 10.1200/JCO.22.02378.
    PubMed     Abstract available
    
    
    
48. JIN EH, Han K, Shin CM, Lee DH, et al
    Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early-Onset Colorectal Cancer.
    J Clin Oncol. 2023 Jun 14:JCO2201895. doi: 10.1200/JCO.22.01895.
    PubMed     Abstract available
    
    
    
49. STINCHCOMBE TE
    Encorafenib and Binimetinib: A New Treatment Option for BRAF(V600E)-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Jun 4:JCO2300983. doi: 10.1200/JCO.23.00983.
    PubMed    
    
    
    May 2023
50. DOTTORINI L, Petrelli F, Ghidini A, Rea CG, et al
    Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
    J Clin Oncol. 2023 May 15:JCO2300354. doi: 10.1200/JCO.23.00354.
    PubMed    
    
    
    April 2023
51. LUDFORD K, Ho WJ, Thomas JV, Raghav KPS, et al
    Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.
    J Clin Oncol. 2023;41:2181-2190.
    PubMed     Abstract available
    
    
    
52. CIOMBOR KK, Eng C
    Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
    J Clin Oncol. 2023;41:2138-2140.
    PubMed    
    
    
    
53. STAHLER A, Hoppe B, Na IK, Keilholz L, et al
    Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
    J Clin Oncol. 2023 Apr 5:JCO2202582. doi: 10.1200/JCO.22.02582.
    PubMed     Abstract available
    
    
    
54. VIKAS P, Messersmith H, Compton C, Sholl L, et al
    Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.
    J Clin Oncol. 2023;41:1943-1948.
    PubMed     Abstract available
    
    
    February 2023
55. HOTCA A, Goodman KA
    Trends in Anal Cancer: Leveraging Public Health Efforts to Improve Cancer Care.
    J Clin Oncol. 2023;41:1180-1182.
    PubMed    
    
    
    
56. VAN CUTSEM E, Taieb J, Yaeger R, Yoshino T, et al
    ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer.
    J Clin Oncol. 2023 Feb 10:JCO2201693. doi: 10.1200/JCO.22.01693.
    PubMed     Abstract available
    
    
    
57. KAMIHARA J, Collins NB
    Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward.
    J Clin Oncol. 2023;41:727-731.
    PubMed    
    
    
    
58. CHUNG J, Negm L, Bianchi V, Stengs L, et al
    Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
    J Clin Oncol. 2023;41:766-777.
    PubMed     Abstract available
    
    
    January 2023
59. MORTON D, Seymour M, Magill L, Handley K, et al
    Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 19:JCO2200046. doi: 10.1200/JCO.22.00046.
    PubMed     Abstract available
    
    
    
60. HALL WA, Smith JJ
    Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma.
    J Clin Oncol. 2023;41:173-180.
    PubMed     Abstract available
    
    
    
61. SOCHA J, Zolciak-Siwinska A, Bujko K
    Radio- or Chemotherapy Dose Escalation for Organ Preservation in Rectal Cancer?
    J Clin Oncol. 2023;41:417.
    PubMed    
    
    
    
62. KAZI M, Saklani A
    Total Neoadjuvant Therapy for All Rectal Cancers: Is This the Way Ahead of the OPRA Trial?
    J Clin Oncol. 2023;41:415-416.
    PubMed    
    
    
    
63. SUTCUOGLU O, Rustamova Cennet N, Ozet A, Ozdemir N, et al
    Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?
    J Clin Oncol. 2023;41:416-417.
    PubMed    
    
    
    
64. KENNECKE HF, O'Callaghan CJ, Loree JM, Moloo H, et al
    Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
    J Clin Oncol. 2023;41:233-242.
    PubMed     Abstract available
    
    
    
65. YU Y, Shi Q, Chen H
    Acquired Genomic Alterations From First-Line Anti-EGFR Chemotherapy in Advanced Colorectal Cancer: Improving Study Design and Data Analysis.
    J Clin Oncol. 2023 Jan 3:JCO2202296. doi: 10.1200/JCO.22.02296.
    PubMed    
    
    
    December 2022
66. SUTCUOGLU O, Ozet A, Yazici O, Ozdemir N, et al
    Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm?
    J Clin Oncol. 2022;40:4027.
    PubMed    
    
    
    
67. YUKSEL BC
    Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective.
    J Clin Oncol. 2022;40:4029.
    PubMed    
    
    
    
68. NEGRI F, Aschele C
    Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer.
    J Clin Oncol. 2022;40:4028.
    PubMed    
    
    
    November 2022
69. DAMGACIOGLU H, Lin YY, Ortiz AP, Wu CF, et al
    State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.
    J Clin Oncol. 2022 Nov 28:JCO2201390. doi: 10.1200/JCO.22.01390.
    PubMed     Abstract available
    
    
    
70. LEE S, Ma C, Shi Q, Kumar P, et al
    Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    J Clin Oncol. 2022 Nov 11:JCO2201637. doi: 10.1200/JCO.22.01637.
    PubMed     Abstract available
    
    
    
71. PARSEGHIAN CM, Sun R, Woods M, Napolitano S, et al
    Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy.
    J Clin Oncol. 2022 Nov 9:101200JCO2201423. doi: 10.1200/JCO.22.01423.
    PubMed     Abstract available
    
    
    October 2022
72. GALLOIS C, Shi Q, Meyers JP, Iveson T, et al
    Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
    J Clin Oncol. 2022 Oct 28:JCO2102726. doi: 10.1200/JCO.21.02726.
    PubMed     Abstract available
    
    
    
73. MORRIS VK, Kennedy EB, Baxter NN, Benson AB 3rd, et al
    Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
    J Clin Oncol. 2022 Oct 17:JCO2201690. doi: 10.1200/JCO.22.01690.
    PubMed     Abstract available
    
    
    September 2022
74. RAGHAV K, Ou FS, Venook AP, Innocenti F, et al
    Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
    J Clin Oncol. 2022 Sep 6:JCO2200365. doi: 10.1200/JCO.22.00365.
    PubMed     Abstract available
    
    
    August 2022
75. TOPHAM JT, O'Callaghan CJ, Feilotter H, Kennecke HF, et al
    Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
    J Clin Oncol. 2022 Aug 25:JCO2200364. doi: 10.1200/JCO.22.00364.
    PubMed     Abstract available
    
    
    
76. AREF A, Abdalla A
    Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Induction or Consolidation Chemotherapy?
    J Clin Oncol. 2022;40:2515-2519.
    PubMed    
    
    
    
77. GARCIA-AGUILAR J, Patil S, Gollub MJ, Kim JK, et al
    Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    J Clin Oncol. 2022;40:2546-2556.
    PubMed     Abstract available
    
    
    
78. OU SI, Janne PA, Leal TA, Rybkin II, et al
    First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1).
    J Clin Oncol. 2022;40:2530-2538.
    PubMed     Abstract available
    
    
    
79. BROWN JC, Ma C, Shi Q, Fuchs CS, et al
    Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Clin Oncol. 2022 Aug 9:JCO2200171. doi: 10.1200/JCO.22.00171.
    PubMed     Abstract available
    
    
    July 2022
80. MALLA M, Loree JM, Kasi PM, Parikh AR, et al
    Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    J Clin Oncol. 2022 Jul 15:JCO2102615. doi: 10.1200/JCO.21.02615.
    PubMed     Abstract available
    
    
    June 2022
81. KIM ST, Kim SY, Lee J, Yun SH, et al
    Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07.
    J Clin Oncol. 2022 Jun 30:JCO2102962. doi: 10.1200/JCO.21.02962.
    PubMed     Abstract available
    
    
    
82. ROSSINI D, Antoniotti C, Lonardi S, Pietrantonio F, et al
    Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study b
    J Clin Oncol. 2022 Jun 6:JCO2200839. doi: 10.1200/JCO.22.00839.
    PubMed     Abstract available
    
    
    
83. CIOMBOR KK, Strickler JH, Bekaii-Saab TS, Yaeger R, et al
    BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.
    J Clin Oncol. 2022 Jun 1:JCO2102541. doi: 10.1200/JCO.21.02541.
    PubMed     Abstract available
    
    
    
84. RAPHAEL MJ, Karanicolas PJ
    Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
    J Clin Oncol. 2022 Jun 1:JCO2102505. doi: 10.1200/JCO.21.02505.
    PubMed     Abstract available
    
    
    
85. JIN Z, Sinicrope FA
    Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
    J Clin Oncol. 2022 Jun 1:JCO2102691. doi: 10.1200/JCO.21.02691.
    PubMed     Abstract available
    
    
    
86. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available
    
    
    
87. ENG C, Ciombor KK, Cho M, Dorth JA, et al
    Anal Cancer: Emerging Standards in a Rare Rare Disease.
    J Clin Oncol. 2022 Jun 1:JCO2102566. doi: 10.1200/JCO.21.02566.
    PubMed     Abstract available
    
    
    May 2022
88. JIN J, Tang Y, Hu C, Jiang LM, et al
    Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
    J Clin Oncol. 2022;40:1681-1692.
    PubMed     Abstract available
    
    
    
89. YOSHINO T, Oki E, Misumi T, Kotaka M, et al
    Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    J Clin Oncol. 2022 May 5:JCO2102628. doi: 10.1200/JCO.21.02628.
    PubMed     Abstract available
    
    
    March 2022
90. SUTCUOGLU O, Ulas Kahya B, Ozdemir N, Yazici O, et al
    Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    J Clin Oncol. 2022 Mar 29:JCO2200047. doi: 10.1200/JCO.22.00047.
    PubMed    
    
    
    
91. MORANO F, Raimondi A, Pagani F, Lonardi S, et al
    Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102583. doi: 10.1200/JCO.21.02583.
    PubMed     Abstract available
    
    
    February 2022
92. COPUR MS, Kelly J, Tun SM
    Treatment Break Versus Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2022 Feb 22:JCO2102420. doi: 10.1200/JCO.21.02420.
    PubMed    
    
    
    January 2022
93. CHENG E, Ou FS, Ma C, Spiegelman D, et al
    Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
    J Clin Oncol. 2022 Jan 7:JCO2101784. doi: 10.1200/JCO.21.01784.
    PubMed     Abstract available
    
    
    December 2021
94. BAXTER NN, Kennedy EB, Bergsland E, Berlin J, et al
    Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Dec 22:JCO2102538. doi: 10.1200/JCO.21.02538.
    PubMed     Abstract available
    
    
    
95. FONTANA E, Meyers J, Sobrero A, Iveson T, et al
    Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
    J Clin Oncol. 2021;39:4009-4019.
    PubMed     Abstract available
    
    
    
96. MULCAHY MF, Mahvash A, Pracht M, Montazeri AH, et al
    Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    J Clin Oncol. 2021;39:3897-3907.
    PubMed     Abstract available
    
    
    November 2021
97. PAN M, Jiang C, Tse P, Achacoso N, et al
    TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer.
    J Clin Oncol. 2021 Nov 29:JCO2102014. doi: 10.1200/JCO.21.02014.
    PubMed     Abstract available
    
    
    October 2021
98. LENZ HJ, Van Cutsem E, Luisa Limon M, Wong KYM, et al
    First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    J Clin Oncol. 2021 Oct 12:JCO2101015. doi: 10.1200/JCO.21.01015.
    PubMed     Abstract available
    
    
    September 2021
99. BOZKURT DUMAN B, Cil T
    Do the Survival Data of Primary Tumor Resection Provide Sufficient Data Without Considering the Tumor Sidedness, Predictive Biomarkers, and Biologic Agents?
    J Clin Oncol. 2021;39:2970.
    PubMed    
    
    
    
100. RAYSON D
     Cardio-Oncology.
     J Clin Oncol. 2021;39:2962-2963.
     PubMed    
     
     
     
101. DURNO C, Ercan AB, Bianchi V, Edwards M, et al
     Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.
     J Clin Oncol. 2021;39:2779-2790.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.